Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI
Summary
Its MicroOrgans technology provides 3D disease models that the company hopes will give researchers a more accurate indication of whether compounds are likely to work in humans. This is especially difficult to determine when it comes to finding drugs that work on rare neurological diseases, which are tricky to replicate in animal models because of the complexity of the human brain, according to Stemonix. The companies plan to use Atomwise’s AI and Stemonix’s human MicroBrain 3D disease model to target Rett syndrome, a severe neurological disorder caused by mutations in the MECP2 gene. The UK’s GW Pharmaceuticals (NASDAQ: GWPH) is studying non-psychoactive parts of cannabis, including cannabidiol and cannabidivarin, as potential treatments. The decision was made following revelations that some of the animal data the company submitted to the FDA in support of onasemnogene abeparvovec (Zolgensma), the gene therapy it developed for babies with spinal muscular atrophy, had been manipulated.
Classifications
AskAI Classifications
LabelsLinked Companies
